LILRA2 and breast carcinoma: A study on oestrogen receptor‐positive breast cancer reported that after receiving neoadjuvant endocrine therapy, compared with patients with low expression of the LILRA2 gene in the tumour biopsies, patients with high LILRA2 expression showed significant tumour shrinkage, which was beneficial to breast‐conserving surgery [31].